Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_assertion description "[Therefore, inhibitors of transglutaminase 2 should be considered as possible therapeutics for OPMD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_assertion evidence source_evidence_literature NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_assertion SIO_000772 20519718 NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_assertion wasDerivedFrom befree-20140225 NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_assertion wasGeneratedBy ECO_0000203 NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.
- befree-20140225 importedOn "2014-02-25" NP558119.RAhx_b6VFxZq5q6FIUr_8SS3jlQSYPtdHUBI1-lD1nkz8130_provenance.